Related Experiment Video
Updated: Feb 2, 2026

Transfecting and Nucleofecting Human Induced Pluripotent Stem Cells
Published on: October 5, 2011
Pediatric Anthracycline-Induced Cardiotoxicity: Mechanisms, Pharmacogenomics, and Pluripotent Stem-Cell Modeling
Anne Tripaydonis1,2, Rachel Conyers1,2,3, David A Elliott1,2
1Murdoch Childrens Research Institute, The Royal Children's Hospital, Parkville, Victoria, Australia.
Abstract:
Anthracycline-induced cardiotoxicity (ACT) is a severe adverse drug reaction for a subset of children treated with anthracyclines as part of chemotherapy protocols. The identification of genetic markers associated with increased ACT susceptibility has clinical significance toward improving patient care and our understanding of the molecular mechanisms involved in ACT. Human-induced pluripotent stem cell-derived cardiomyocytes represent a novel approach to determine the pharmacogenomics of ACT and guide the development of genetic screening tests.
Insights
Identifying genetic markers for anthracycline-induced cardiotoxicity (ACT) is crucial for children undergoing chemotherapy. Human-induced pluripotent stem cell-derived cardiomyocytes offer a new way to study ACT pharmacogenomics and develop genetic screening tests.
Area of Science:
- Pharmacogenomics
- Cardiology
- Pediatric Oncology
Background:
- Anthracycline chemotherapy can cause severe cardiotoxicity (ACT) in some children.
- Understanding genetic susceptibility to ACT is vital for improving patient care.
- Current methods for predicting ACT risk require enhancement.
Purpose of the Study:
- To identify genetic markers associated with increased susceptibility to anthracycline-induced cardiotoxicity.
- To explore the utility of human-induced pluripotent stem cell-derived cardiomyocytes in studying ACT pharmacogenomics.
- To guide the development of genetic screening tests for ACT risk.
Main Methods:
- Utilizing human-induced pluripotent stem cell-derived cardiomyocytes as a model system.
- Investigating the pharmacogenomic basis of anthracycline-induced cardiotoxicity.
- Analyzing genetic variations potentially linked to ACT susceptibility.
Main Results:
- Preliminary findings suggest specific genetic markers may correlate with ACT risk.
- Human-induced pluripotent stem cell-derived cardiomyocytes demonstrate potential for personalized drug response assessment.
- The study provides a foundation for further research into ACT genetic predictors.
Conclusions:
- Genetic factors play a significant role in anthracycline-induced cardiotoxicity susceptibility.
- Human-induced pluripotent stem cell-derived cardiomyocytes offer a promising platform for pharmacogenomic studies of ACT.
- Development of genetic screening tests could personalize chemotherapy regimens and mitigate cardiac risks in pediatric patients.
More Related Videos
Related Concept Videos
Induced Pluripotent Stem Cells
Induced Pluripotent Stem Cells
Somatic...
Embryonic Stem Cells
The Quantum-Mechanical Model of an Atom
Mechanisms of Retrovirus-induced Cancers
Adult Stem Cells

